BioCryst Initiates Enrollment In Pivotal Trial Of Forodesine HCL In Patients With Cutaneous T-Cell Lymphoma (CTCL)

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that it has initiated enrollment of the pivotal trial of its lead oncology drug candidate, forodesine HCL, in the treatment of patients with cutaneous T-cell lymphoma (CTCL). The multinational trial, which will evaluate once daily oral forodesine HCL treatment, will be conducted in accordance with a Special Protocol Assessment (SPA) agreement between the U.S. [click link for full article]

More: continued here

Filed under: Lymphoma / Leukemia on October 20th, 2007